<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421900</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0090</org_study_id>
    <nct_id>NCT02421900</nct_id>
  </id_info>
  <brief_title>Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is 1) to characterize T-cell response in patients with atrial
      fibrillation, and 2) to analyze the changes of T-cell response after radio-frequency catheter
      ablation of atrial fibrillation. First, immune-phenotyping and cytokine profiling of T cells
      from patients with atrial fibrillation will performed. Next the difference of T-cell immunity
      among various type of atrial fibrillation patients will be analyzed. Finally the changes of
      T-cell response and cytokines after radio-frequency catheter ablation of atrial fibrillation
      will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency (%) of specific marker-expressing cells among CD4 or CD8 T-subsets</measure>
    <time_frame>1 year</time_frame>
    <description>Immunosenescence marker: CD28, CD57
Activation marker: CD38, HLA-DR
Differentiation marker: CCR7, CD45RA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency (%) of cytokine-secreting cells among CD4 or CD8 T-subsets</measure>
    <time_frame>1 year</time_frame>
    <description>Proinflammatory cytokine: IFN-gamma, TNF-alpha
Cytotoxic molecule: granzyme B, perforin</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <description>Atrial fibrillation patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>radio-frequency catheter ablation of atrial fibrillation</intervention_name>
    <description>radio-frequency catheter ablation of atrial fibrillation</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      40cc blood sampling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who consent with study

          -  patients with age more than19

          -  patients who undergoing catheter ablation of atrial fibrillation due to symptomatic,
             drug refractory atrial fibrillation

        Exclusion Criteria:

          -  Patients who do not agree with study inclusion

          -  Permanent AF refractory to electrical cardioversion

          -  AF with rheumatic valvular disease

          -  Patients with left atrial diameter greater than 60mm

          -  Patients with age less than 19

          -  Patient with malignant tumor and chronic infection disease

          -  Patient are given immune inhibitor and steroidal anti-inflammatory drug within 2weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui-Nam Pak, MD, PhD</last_name>
    <phone>82-2-2228-8459</phone>
    <email>hnpak@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Cardiovascular Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Nam Pak, M.D., Ph.D.</last_name>
      <phone>82-2-2228-8459</phone>
      <email>hnpak@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>July 15, 2018</last_update_submitted>
  <last_update_submitted_qc>July 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

